Search results
Results from the WOW.Com Content Network
The drug or other substance has a currently accepted medical use in treatment in the United States. Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule III.
It also maintains List I of chemicals and List II of chemicals, which contain chemicals that are used to manufacture the controlled substances/illicit drugs. The list is designated within the Controlled Substances Act [ 1 ] but can be modified by the U.S. Attorney General as illegal manufacturing practices change.
This is the list of Schedule I controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [2]
This image or file is a work of a Drug Enforcement Administration employee, taken or made as part of that person's official duties. As a work of the U.S. federal government , the image is in the public domain in the United States.
The following 16 pages use this file: Australian National Task Force on Cannabis; Buprenorphine; Legalization of non-medical cannabis in the United States; Substance abuse; Substance abuse prevention; Talk:Drug/Archive 1; Talk:Drug harmfulness/Archive 1; Talk:Illegal drug trade/Archive 1; Talk:LSD/Archive 5; Talk:Methylphenidate/Archive 3
A drug combination chart designed for harm reduction by TripSit [1] Polysubstance use or multisubstance use is the use of combinations of psychoactive substances with both legal and illegal substances. This page lists polysubstance combinations that are entheogenic, recreational, or off-label indicated use of pharmaceuticals.
UN World Drug Report 2016. In Peru, coca-bush cultivation jumped 44% between 2000 and 2011. While cultivation fell 31% between 2011 and 2014 (back to 2000 levels), it still accounts for 32% of ...
A higher weight indicates a larger difference between the most harmful drug on the criterion and no harm. This chart is supported by the data taken from the study "Drug harms in the UK: a multi-criteria decision analysis", by David Nutt, Leslie King and Lawrence Phillips, on behalf of the Independent Scientific Committee on Drugs.